leisure time -WSS

leisure time

author：hotspot 2025-09-05 11:27:05 - browse：4

Joe Biden in 2016. -- first opinion coverage from STAT — President Joe Biden Elise Amendola/AP

WASHINGTON — The latest phase of President Biden’s Cancer Moonshot initiative leaves open a few questions on how Congress might move forward with the program.

Since its launch in 2016, the federally funded cancer moonshot program has spurred thousands of scientific publications, 49 clinical trials, and more than 30 patent filings, according to a new report from the Congressional Research Service, the nonpartisan research arm of Congress.

The next phase of the cancer moonshot, according to Biden and his administration, is meant to emphasize cancer screening, prevention, and equitable treatment. The updated plan also seeks to speed progress on treatments for rare and childhood cancers, and it calls for supporting patients, survivors, and caregivers. The Advanced Research Projects Agency for Health (ARPA-H), a new agency tasked with taking big risks on biomedical and health technology, is also committing $240 million to cancer-related research and investing in new data-sharing platforms and a nationwide network for clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： The SUPPORT Act is critical to fighting the opioid crisis

WSS

New Medicare drug pricing powers could soon be upended in court

Health and fitness trackers are measuring the wrong things

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

How I ended up pumping milk in a bathroom stall at JPM 2024

JPM 2024: Verve Therapeutics looks to mainstream genome editing

JPM 2024: Nvidia claims we're in biological revolution. Are we?

hotspot

leisure time

focus

In age of alternative facts, a scholarly course on calling out crap

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

In age of alternative facts, a scholarly course on calling out crap

Three issues to watch in global health in 2024

Hollywood unions extend contract negotiations for actors

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

United colonoscopy coverage change 'may cost lives,' doctors say

Idaho abortion case may prompt more restrictions in other states

entertainment

Risky weight loss products often used by teens globally, per study

DeSantis can now import cheaper drugs. But will Biden get credit?

New menopause drug shows promise in relief for hot flashes

The SUPPORT Act is critical to fighting the opioid crisis

Doulas covered by Medicaid under New York's new plan

Readout LOUD podcast: live from JPM 2024

entertainment

focus

explore

hotspot